Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

In response to the Ebola virus (EBOV) crisis 2013-2016, a recombinant vesicular stomatitis virus (VSV)-based EBOV vaccine was clinically tested. A single-dose regimen of VSV-EBOV revealed a safe and immunogenic profile and demonstrated clinical efficacy. While EBOV-specific immune responses to this candidate vaccine have previously been investigated, limited human data on immunity to the VSV-vector are available. Within the scope of a Phase I study, we performed a comprehensive longitudinal analysis of humoral and cellular immune responses to internal VSV-proteins following VSV-EBOV immunization. While no pre-existing immunity to the vector was observed, up to 1/3 of subjects showed VSV-specific CTL-responses and antibodies.

Original publication





Journal of Infectious Diseases


Oxford University Press

Publication Date





556 - 561


pre-existing immunity, vector-immunity, VSV-EBOV, Ebola virus, vesicular stomatitis virus, V920, vaccine